For lipid peroxidation analysis, the cells were treated with 15 M RMC-4550, 10 nM trametinib, 10 nM RMC-7977, 10 M MRTX1133, or a combination of an SHP2 inhibitor and trametinib for 48 h
Temporary fatigue or paradoxical tiredness in the first few sessions
GLP-1 receptor agonists e.g., semaglutide, liraglutide commonly cause gastrointestinal adverse effects such as nausea, vomiting, diarrhea, constipation, and abdominal discomfort, especially during dose escalation, less common risks include pancreatitis, gallbladder disease, and hypoglycemia mainly with insulin sulfonylureas
By adhering to these standards, we can maximize the therapeutic potential of peptides while minimizing risks
Franciscus A, Highleyman L